Conclusions
TNBC, DLTs
In summary, the combination of fuzuloparib and apatinib showed hematologic DLTs and acceptable safety in patients with recurrent OC and TNBC. Fuzuloparib 100 mg bid plus apatinib 500 mg qd was determined to be the RP2D. With the activity observed in OC and TNBC, further investigation of the combination therapy is warranted as a potential alternative to cytotoxic treatment.